Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AbbVie Seeks Ulcerous Colitis Indication for Rinvoq in Japan
October 28, 2021
- Nobelpharma Plans Launch of 3 Products in US, China, Europe: R&D Head
October 27, 2021
- Solasia Grants Japan Rights for Darinaparsin to Nippon Kayaku, Ends Deal with Meiji
October 27, 2021
- Daiichi Sankyo, AstraZeneca to Launch PIII of DS-1062/Keytruda Combo
October 27, 2021
- Sun Pharma Japan to Boost Sales Force, Development to Achieve 1.5-Fold Sales Growth by 2025
October 27, 2021
- Oncolys’ Oral COVID-19 Drug Effective in Hamster Model
October 27, 2021
- MSD Seeks Japan Approval for 15-Valent Pneumococcal Vaccine
October 27, 2021
- Extension of Use Patent Term for Remitch Affirmed: Toray
October 27, 2021
- Choseido Revamps Management, Sacks President Harada over GMP Violations
October 26, 2021
- Sanofi, Nichi-Iko to Dissolve Joint Venture at Year-End
October 26, 2021
- KM Biologics Eyes COVID-19 Booster Filing as Early as Spring, Trial Start Slated by Year-End
October 26, 2021
- Keytruda Filed for Neoadjuvant/Adjuvant Therapy for TNBC in Japan
October 26, 2021
- Rakuten Medical, Karkinos Tie Up in Novel Cancer Care in India
October 25, 2021
- Chugai’s 9-Month Sales Up 17.5% on Ronapreve, 42.8 Billion Yen Booked in Govt Purchase
October 25, 2021
- KM Biologics’ COVID-19 Jab Enters Japan PII/III Study
October 25, 2021
- MSD Seeks Cervical Cancer Nod for Keytruda in Japan
October 25, 2021
- Kaken’s Approval-Pending Eschar Remover Hits Goal in PIII Study
October 22, 2021
- Shionogi Launches Japan PII/III for COVID-19 Vaccine
October 22, 2021
- Daiichi Sankyo Eyes Booster Dose Trial Launch in January
October 22, 2021
- Mundipharma Japan Set to Cut into High Production Costs, Boost Profitability to Lure Investments: President
October 22, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…